In summary, the majority of the studies have found that patients with MetS are at increased risk for developing CVD [11, 37, 3955]
BC/BS Health Insurance GLP 1 Change in Coverage Beginning on July 1, 2026, our Blue Cross Blue Shield plan will no longer be covering GLP 1 medications for weight loss
28,31-35 Trial evidence The LEADER trial examined once-daily liraglutide in patients with established atherosclerotic CVD, chronic kidney disease, heart failure or significant cardiovascular risk factors
Vaughan-Shaw P, Fecher I, Harris S, et al
Irregular periods may indicate underlying conditions like PCOS, thyroid disorders, and other hormonal imbalances
The state initiated tests in March on hundreds of private wells, revealing that over half contain PFAS levels exceeding Environmental Protection Agency (EPA) standards